Abstract: The invention is generally related to a soft hydrogel ocular insert that is composed of at least one hydrogel material in fully hydrated state and can be comfortable for wearing. The hydrogel material comprises polymer chains, which are derived from at least one arylborono-containing hydrophilic copolymer and at least one mucoadhesive polymer, and cyclic boronic ester crosslinks for crosslinking those mucoadhesive polymer chains and arylborono-containing hydrophilic copolymer chains to form a 3-dimensional polymer network. Those cyclic boronic ester crosslinks can be hydrolyzed slowly in the tear of the eyes of a patient, resulting in the disintegration (dissolution) of the 3-dimensional polymer network and thereby providing mucoadhesisve polymers and optionally drugs impregnated in the hydrogel ocular insert in a controlled manner.

Abstract: The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye.

Abstract: The present invention relates to certain DPP-4 inhibitors for treating and/or preventing oxidative stress, vascular stress and/or endothelial dysfunction as well as to the use of such DPP-4 inhibitors in treatment and/or prevention of diabetic or non-diabetic patients, including patient groups at risk of cardiovascular and/or renal disease.

Abstract: Chlorella vulgaris aqueous extracts are used for enhancing C. longa plant growth and rhizome yield. In C. longa, Chlorella vulgaris foliar spraying stimulates plant growth and yield, as well as changing the compositions of bioactive compounds. Plant growth, yield, photosynthetic pigment concentration, and nitrogen content all improved when the Chlorella vulgaris aqueous extract was added to the foliar spray. The CURS-1, -2, -3, and DCS genes were revealed to be differently upregulated by the Chlorella vudgaris aqueous extract treatments. The curcuminoid content (hisdenethoxycurcumin, dimethoxycurcumin, and curcumin) also increased when the plant was sprayed with the Chlorella vulgaris aqueous extract, which corresponded with the curcuminoid gene's expression level.

Abstract: The invention is directed to an aqueous extract of Eruca sativa (arugula) leaves that has antimicrobial activity on Gram-positive bacteria and mycoplasmas. The extract may be purified away from solid or insoluble components, standardized based on the weight of its non-aqueous or solid content, assayed for antimicrobial activity, and provided in an aseptic or sterile form for pharmaceutical use. It may be used to kill or inhibit the growth of microorganisms such as Gram positive bacteria, promote wound healing, or as prophylaxis against host colonization or infection by a microorganism.

Abstract: The present invention relates to a topical pharmaceutical composition to be used in the anal region for anal fissures and hemorrhoids, including the postoperative period of hemorrhoidectomy. The pharmaceutical composition comprises an anal dilator, a mucoadhesive polymer and a non-aqueous vehicle. Also described is a method of manufacturing the pharmaceutical composition.

Abstract: A trans-mucosal testosterone delivery composition for humans or animals having from about 50 to 99 wt. % humectant, from about 1 to 50 wt. % water, from about 0.001 to 25.00 wt. % testosterone, from about 0 to 25 wt. % oil, and from about 25 to 1 wt. % surfactant, wherein the composition is hydrophobic and has release properties.

Abstract: A growth-promoting bacterial agent capable of improving content of soybean oil, preparation method, and use thereof are provided. The growth-promoting bacterial agent is fermented by a DW1 strain, the classification name of the DW1 strain is Bacillus sp., the DW1 strain is deposited in the China Center for Type Culture Collection on Jul. 16, 2021, and the deposit number is CCTCC NO: M 2021889. The growth-promoting bacterial agent of the present disclosure has the ability to dissolve insoluble phosphorus and insoluble potassium and can increase content of readily available phosphorus and readily available potassium in the soil, which has an obvious promoting effect on the growth of soybean and improves soybean yield. The growth-promoting bacterial agent of the present disclosure promotes bacteria and can significantly improve the content of soybean oil. At the same time, it has an affinity of soybean agglutinin and can agglutinate with the soybean agglutinin.

Abstract: The invention relates to the use of a crushed material obtained from at least one part of rocket plants, for example of the genera Eruca (Eruca Eruca vesicaria, etc.), Diplotaxis (Diplotaxis erucoides, Diplotaxis tenuifolia, Diplotaxis muralis, etc.), Bunias (Bunias erucago, Bunias orientalis, etc.), Erucastrum (Erucastrum nasturtiifolium, Erucastrum incanum, etc.) or Cakile, in order to promote plant growth or root growth.

Abstract: Injectable compositions that can be added to parenteral nutrition are provided. In particular, a stable injectable composition is provided which includes water, and at least one of about 800 ?g to about 4,000 ?g of zinc, about 40 ?g to about 400 ?g of copper, from about 4 ?g to about 90 ?g of selenium, or from about 1 ?g to about 80 ?g of manganese per 1 mL of the injectable composition. Methods of preparing and using of the stable injectable composition are also provided.

Abstract: An L-menthol pharmaceutical dosage form includes an effective amount of L-menthol for treating a gastrointestinal disorder. The L-menthol is within a plurality of particulates having a core and an enteric coating over the core. The core includes an L-menthol source that is at least 80% pure L-menthol. The dosage form may be used to treat gastrointestinal disorders, such as irritable bowel syndrome.

Abstract: Compositions that comprise salts, compounds and complexes of 64Zn-enriched zinc, such as 64Zn-enriched zinc aspartate, and further optionally include 85Rb-enriched rubidium salt compounds of general formula 1, below, wherein each of R1 through R14 is independently selected from H, OH, F, Cl, Br, I, C1-C6 alkyl, C1-C6 alkoxy, and NO2, such as the compound of Formula 1 in which R3 is CH3 and all other R groups are H for use to treat a neurodegenerative disease (NDD), such as Parkinson's disease (PD). Methods that entail administering such compositions to treat an NDD, such as PD, optionally in combination with any other treatment for an NDD such as for PD.

Abstract: The subject invention provides topical therapeutic compositions and methods of their use for enhanced healing of wounds, including burns, and scars of the skin. Specifically, in one embodiment, the subject invention provides materials and methods for reducing the healing time of skin wounds and for reducing the appearance of scars. The subject invention utilizes topical compositions comprising microbial growth by-products and, optionally, a topically-acceptable carrier. In specific embodiments, the microbial growth by-products are biosurfactants.

Abstract: Methods for improving the ability of a population of biological agents to compete and survive in a field setting are provided. The modified population of agents is able to grow, compete with other microbial strains and fungi, and provide protection for plants from pathogens. Modified biological agents and modified populations of such agents that are herbicide tolerant or resistant are selected or engineered. In this manner, the protection from disease-causing agents is enhanced. Such modified populations can be added to soils to prevent fungal pathogens and associated diseases, promoting plant growth. The present invention is useful for enhancing the competitiveness of modified biological agents particularly over other microbial agents which are not herbicide resistant. Compositions include selected or engineered herbicide resistant biological agents and modified populations of biocontrol agents. These modified biological agents can be used as an inoculant or as a seed coating for plants and seeds.

Abstract: Disclosed herein are compositions of rAAV particles and methods for administrating rAAV particles having enhanced transduction properties.

Abstract: A composition for treating ulcerative colitis can include zinc oxide nanoparticles; and sulfasalazine adsorbed onto a surface of the zinc oxide nanoparticles. The composition can be administered to a patient to treat ulcerative colitis or symptoms associated with ulcerative colitis. The composition can be administered at about 100 mg/kg of zinc oxide nanoparticles and up to about 12.2 mg/kg of sulfasalazine. These compositions exhibit synergistic effects in treating ulcerative colitis.

Abstract: Described herein is crystalline sodium (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyl)oxy)-2-methylphenoxy)acetate, uses of such crystalline material in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with a PPAR? agonist compound.

Abstract: A new composition and method for cleaning hair grooming implements is provided. The composition comprises about 1.1% Sodium Hypochlorite, about 2.5% Sodium Hydroxide, about 0.5% Lithium Perchlorate and about 95.9% water. A concentrated version of the solution may be formed and later diluted for use. The addition of surfactant to the solution increases stability and efficiency.

Abstract: In various aspects, the present disclosure pertains to methods of treating or preventing bleeding at a tissue site comprising applying a chitosan powder composition to the tissue site. In various aspects, the present disclosure pertains to chitosan powder compositions for application to a tissue site, where the powder compositions comprise a chitosan salt, a crosslinked chitosan, a derivatized chitosan, or a combination thereof. In various aspects, the disclosure pertains to catheter assemblies, which are preloaded with a chitosan powder composition and which are configured to deliver the chitosan powder composition a tissue site.

Abstract: The invention provides isolated Erwinia persicina strains with activity against: a) at least one Xanthomonas species, and/or b) at least one Brassicaceae pathogen. In particular the invention provides the isolated E. persicina strains deposited as DSM 32302, DSM 32304, DSM 32305 and DSM 32303. The invention provides compositions comprising one or more strains of the invention. The invention also provides methods of use of one or more strains or compositions of the inventions to control plant pathogens, particularly Xanthomonas campestris pv. campestris.